Physician profile
Josephine E Watson
NPI 1699915066
$851.96
in general payments reported to CMS, 2019-2025
15 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.65 · 2020: $18.15 · 2021: $108 · 2022: $128 · 2023: $83.54 · 2024: $220 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $571.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $161.34 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Dexcom, INC. | $138.53 | 2022-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $113.91 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $74.43 | 2019-2023 | Gardasil 9, Vaxelis, Vaxneuvance |
| Abbvie INC. | $71.54 | 2022-2023 | Vraylar |
| Glaxosmithkline, LLC. | $61.52 | 2019-2024 | Arexvy |
| Organon LLC | $41.85 | 2025 | Nexplanon |
| Astrazeneca Pharmaceuticals LP | $40.22 | 2024-2025 | Breztri |
| Novo Nordisk INC | $33.55 | 2021-2022 | |
| Cipher Pharmaceuticals US LLC | $32.08 | 2025 | Natroba, Spinosad |
| Averitas Pharma INC. | $22.18 | 2025 | Qutenza |
| Novartis Pharmaceuticals Corporation | $16.71 | 2021 | |
| Sanofi Pasteur INC. | $15.73 | 2025 | |
| Exeltis, USA INC. | $14.44 | 2021 | |
| Exact Sciences Corporation | $13.93 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josephine Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.